Fig. 2: Treatment pathways of registered patients. | BJC Reports

Fig. 2: Treatment pathways of registered patients.

From: Results and lessons learnt from the WISTERIA phase I trial combining AZD1775 with cisplatin pre- or post-operatively in head and neck cancer

Fig. 2

Swimmer plots detailing the treatment pathways of patients registered to the WISTERIA trial. See Supplementary Appendix D for the patients’ full pathways including follow-up. All patients in Group A received 100 mg AZD1775 bd for three days during weeks one and two. Four patients in Group B received 75 mg AZD1775 bd for three days during weeks one and two. One patient received 75 mg AZD1775 bd for three days during weeks one, two, and four. One patient withdrew from the trial prior to receiving any treatment.

Back to article page